- Home
- JANX vs ACHC Comparison
JANX vs ACHC Comparison
Compare JANX & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- ACHC
- Stock Information
- Founded
- JANX 2017
- ACHC 2005
- Country
- JANX United States
- ACHC United States
- Employees
- JANX N/A
- ACHC N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- ACHC Medical Specialities
- Sector
- JANX Health Care
- ACHC Health Care
- Exchange
- JANX Nasdaq
- ACHC Nasdaq
- Market Cap
- JANX 1.4B
- ACHC 1.7B
- IPO Year
- JANX 2021
- ACHC N/A
- Fundamental
- Price
- JANX $27.01
- ACHC $23.56
- Analyst Decision
- JANX Strong Buy
- ACHC Strong Buy
- Analyst Count
- JANX 11
- ACHC 12
- Target Price
- JANX $76.55
- ACHC $35.33
- AVG Volume (30 Days)
- JANX 927.5K
- ACHC 2.4M
- Earning Date
- JANX 11-05-2025
- ACHC 11-05-2025
- Dividend Yield
- JANX N/A
- ACHC N/A
- EPS Growth
- JANX N/A
- ACHC N/A
- EPS
- JANX N/A
- ACHC 1.52
- Revenue
- JANX $439,000.00
- ACHC $3,229,609,000.00
- Revenue This Year
- JANX N/A
- ACHC $7.23
- Revenue Next Year
- JANX $91.66
- ACHC $6.95
- P/E Ratio
- JANX N/A
- ACHC $15.44
- Revenue Growth
- JANX N/A
- ACHC 5.64
- 52 Week Low
- JANX $21.73
- ACHC $17.13
- 52 Week High
- JANX $71.71
- ACHC $54.15
- Technical
- Relative Strength Index (RSI)
- JANX 59.54
- ACHC 45.67
- Support Level
- JANX $25.62
- ACHC $23.50
- Resistance Level
- JANX $27.70
- ACHC $25.21
- Average True Range (ATR)
- JANX 1.56
- ACHC 1.08
- MACD
- JANX 0.30
- ACHC -0.31
- Stochastic Oscillator
- JANX 69.68
- ACHC 1.51
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.